Gastroscholar

Pouchitis is the common inflammatory complication after IPAA for ulcerative colitis. Diagnose it with pouchoscopy, not stool count. AGA 2024 (Barnes, PMID 38128971) treats acute pouchitis with antibiotics and moves chronic antibiotic-dependent or refractory disease toward advanced therapy. EARNEST (Travis, PMID 36988594) is the vedolizumab RCT: mPDAI remission 31% versus 10% at week 14.

Original GastroScholar summary card for pouchitis after IPAA. Not an endoscopic photograph.
Original GastroScholar summary card. Not an endoscopic photograph. No reuse-cleared pouchoscopy still was available for this page.

Experienced teaching points

Clinical Pearls

  1. Four to six stools a day can be a working pouch. Do not start chronic antibiotics on frequency alone.
  2. Look at the pouch, the afferent limb, and the cuff. Ulcers only in the cuff is cuffitis. Strictures, fistula, or pre-pouch ileitis is Crohn's-like disease of the pouch.
  3. Acute idiopathic pouchitis: a fluoroquinolone (or metronidazole) for about 2 weeks. AGA 2024.
  4. EARNEST: vedolizumab 300 mg with 4 weeks of ciprofloxacin beat placebo for chronic pouchitis (31% vs 10% mPDAI remission at week 14).
  5. Dysplasia surveillance of the pouch and cuff is not this page. IBD surveillance.

GI Endoscopy · 7 min read

Pouchitis: Scope It, Antibiotics for Acute, Vedolizumab for Chronic

A J-pouch stools more than a colon. Frequency is not inflammation until pouchoscopy says it is. Cuffitis and Crohn's-like disease are not pouchitis.

Clinical Bottom Line

Problem Move
Suspect pouchitis Pouchoscopy. PDAI (Sandborn 1994, PMID 8170189) is 18 points (symptoms, endoscopy, histology). Traditional active disease is 7 or more. mPDAI drops histology (0-12) and is what EARNEST used.
Acute idiopathic pouchitis Antibiotics. Ciprofloxacin is the usual first pick for about 14 days. Metronidazole works and is harder to stay on. AGA 2024 (PMID 38128971).
Chronic antibiotic-dependent or refractory Do not stay on rotating antibiotics forever without a plan. AGA suggests advanced IBD therapy. EARNEST: vedolizumab 31% vs 10% mPDAI remission at week 14 (PMID 36988594).
Cuffitis Treat like residual ulcerative colitis: topical mesalamine or topical steroid first.
Crohn's-like disease of the pouch Stricture, fistula, pre-pouch ileitis. Biologics, not another 14-day antibiotic course as the whole plan.

Why can't I treat on symptoms?

A healthy pouch is not a colon. Baseline frequency, urgency, and night stools overlap with pouchitis. The leftover stub on this URL treated PDAI as a mandated 18-point ritual and stopped there. PDAI is a trial instrument. In clinic you still have to look. Friability, ulcers, and loss of vascular pattern in the pouch body support the diagnosis. Biopsies help when Crohn's-like disease or CMV is on the list, and they complete a full PDAI if you need one.

Photograph the pouch body, the inlet, the outlet, and the cuff as separate territories. That is how you stop calling everything pouchitis.

What did AGA 2024 and EARNEST change?

Barnes 2024 (PMID 38128971) is an AGA guideline, not an ACG one. Acute pouchitis: antibiotics. Prevention of recurrent pouchitis is where probiotics get a suggestion, not as acute monotherapy. Chronic antibiotic-dependent and antibiotic-refractory disease move to advanced immunosuppressive therapy. Cuffitis follows UC topical pathways. Crohn's-like disease follows Crohn's pathways.

EARNEST (Travis, NEJM 2023, PMID 36988594): 102 adults with chronic pouchitis after IPAA for UC. Vedolizumab 300 mg versus placebo, both with ciprofloxacin for the first 4 weeks. Primary endpoint mPDAI remission at week 14: 31% versus 10%. That is why vedolizumab is the named advanced-therapy example on this page. It is not a claim that every other biologic failed. It is the RCT you can quote.

Do not use oral mesalamine as the primary treatment of idiopathic pouchitis. Do not skip the cuff. Do not restage UC treat-to-target or pouch dysplasia here.

Selected references

  1. Barnes EL, et al. AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders. Gastroenterology. 2024;166:59-85.
  2. Travis S, et al. Vedolizumab for the Treatment of Chronic Pouchitis. N Engl J Med. 2023;388:1191-1200. EARNEST.
  3. Sandborn WJ, et al. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc. 1994;69:409-415.

Last reviewed September 20, 2026. Written for clinicians whose UC patient with a pouch is having more stools and wants a prescription without a look.

For your teaching file

Save this article as a PDF

Drop your email and we'll open a print-ready version you can save as a PDF — and you'll start getting our weekly GI endoscopy newsletter.

Save as PDF

Endoscopic Grading of the Ileal Pouch (PDAI)

Enter your email — we'll open a clean print-ready version of this article. Choose Save as PDF in the print dialog to download.

Free, no spam. Gastroscholar newsletter. Unsubscribe anytime.

← All articles